Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There is no clear evidence that growth hormone replacement therapy for treatment-related growth hormone deficiency in patients with childhood intracranial malignancies has a role in tumour relapse or second malignancy. A 16-year-old girl with an intracranial germinoma was treated with local radiotherapy and subsequently received growth hormone replacement therapy as an adult. Three years after starting growth hormone therapy, 23 years after her radiotherapy treatment, the patient's tumour recurred. Surveillance requirements for patients receiving growth hormone in this setting are discussed.


Journal article


Med Pediatr Oncol

Publication Date





41 - 44


Adolescent, Adult, Brain Neoplasms, Fatal Outcome, Female, Germinoma, Growth Hormone, Humans, Hypopituitarism, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Sella Turcica